Ambrx Inc., is a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code. Ambrx technology uses an expanded genetic code to incorporate synthetic amino acids into protein, all completed within a living cell. These synthetic amino acids enable the creation of Precision Biologics, an exciting new class of therapeutics with broad application and potential. This includes next-generation antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as smart cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $297M
Founded date: 2003
Investors 5
| Date | Name | Website |
| - | M Ventures | m-ventures... |
| - | 5AM Ventur... | 5amventure... |
| 09.02.2022 | Matrix Par... | matrixpart... |
| - | HBM Partne... | hbmpartner... |
| - | Presidio P... | presidiopa... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.11.2020 | - | $200M | - |
| 05.08.2016 | - | $45M | - |
| 06.07.2006 | - | $52M | - |
Mentions in press and media 21
| Date | Title | Description |
| 06.03.2024 | Ambrx Shareholders Approve Acquisition by Johnson & Johnson | - |
| 09.01.2024 | Why Carta’s public battle might be a private markets nightmare | To say the Carta news that broke over the weekend has caused a furor in the startup world is an understatement. The accusation that the cap table management and software unicorn was using customers’ confidential data to bolster its own busi... |
| 08.01.2024 | J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx Acquisition | Big pharmaceutical companies splashed out big bucks in 2023 to acquire or license antibody drug conjugates, or ADCs. The trend is continuing into the new year with Johnson & Johnson reaching a $2 billion deal to acquire clinical-stage A... |
| 20.06.2023 | This Startup Is Rewriting The Language Of Life To Make Smart Biologics | Pearl Bio co-founders: Michael Jewett, Amy Cayne Schwartz, and Farren Isaacs.Pearl Bio. |
| 19.10.2022 | Biotech layoffs continue as Ambrx cuts staff and part of its pipeline to extend its cash | It’s been no secret that this year has been rough for biotechs and employees, as companies have been cutting costs and headcounts throughout the year. Wednesday’s news shows that the trend is, unfortunately, continuing. San ... |
| 21.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange | Ambrx Biopharma (NYSE: AMAM), a private company in the portfolio of HBM Healthcare Investments, completed its initial public offering on the New York Stock Exchange last Friday. The company raised USD 126 million in new capital through the ... |
| 07.01.2021 | Ambrx Appoints Gary Yeung as Chief Financial Officer and Chief Operating Officer | |
| 24.11.2020 | After 5 quiet years, a former Scripps spinout raises $200M and announces plans to try again at an IPO | The first time San Diego biotech Ambrx tried to go public in 2014, they failed and the company’s board switched to a radically different strategy: They sold themselves for an undisclosed amount to a syndicate of Chinese inv... |
| 23.11.2020 | Ambrx has raised a massive $200M round to advance work on its genetics-based therapies | - |
| 23.11.2020 | $200M investment to advance clinical programs for Ambrx | Investors in the $200 million round include Fidelity Management & Research Co., Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partners and Suvretta Capital Management, as well as funds and accounts managed... |
Show more